{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Study Finds Link Between Lorazepam & Worse Outcomes in Pancreatic Cancer
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
Method of Participation in the Learning Process/Evaluation Method Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form. Getting the Most out of the Activity As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed. While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.Learning Objectives
After completing this continuing education activity you will be able to:
- Explain initial study findings demonstrating a relationship between benzodiazepines and survival outcomes in cancer patients and summarize their implications for clinical practice and research.
- Identify the associated issues related to pancreatic cancer tumor microenvironment and cancer-associated fibroblast signaling.
Disclosures
The author, faculty, staff, and planners have no relevant financial relationships with any ineligible organizations regarding this educational activity.
Price:
$10.00
Credits:
- ACCME 1.0 CME
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Professions:
Physician
Test Code: OT1023
Published: October 2023
Expires: 9/30/2025
Sources:
Oncology Times
Required Passing Score: 4/5 (80%)
Categories:
Hematology
,
Oncology
Specialties:
Hematology,
Oncology
Topics:
Lorazepam
,
Pancreatic Cancer